SPR720
An investigational oral first-line candidate for NTM pulmonary disease (PD), a rare disease
SPR720 has the potential to be the first approved oral agent for first-line treatment of NTM-PD, an indication with significant unmet need. With a novel mechanism of action (inhibition of DNA Gyrase [GyrB]), SPR720 is a promising candidate for treatment of NTM-PD due to Mycobacterium avium complex (MAC) or Mycobacterium abscessus.
Tebipenem HBr
An investigational oral carbapenem being developed for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP)
Tebipenem HBr (tebipenem pivoxil hydrobromide) is an investigational oral carbapenem being developed for the treatment of cUTI and AP to potentially help patients avoid hospitalizations and/or reduce the duration of in-patient therapy. If approved, Tebipenem is positioned to be the first oral carbapenem for this condition.
SPR206
An investigational intravenous (IV) product candidate for treating MDR gram-negative infections
SPR206 is an investigational IV direct-acting antibiotic being developed against gram-negative bacterial infections in participants with hospital-acquired or ventilator-associated bacterial pneumonia. SPR206 has shown activity against MDR gram-negative pathogens, including carbapenem-resistant ones, in preclinical studies. An Investigational New Drug application has been cleared by the FDA to advance SPR206 into a Phase 2 clinical trial.
Partnerships
Spero Therapeutics believes that forming collaborations with external partners is essential to maximizing the reach and impact of our innovative therapies for patients.
Investor Relations
Stock information, SEC filings, corporate governance, IR resources and more.
Careers
Join our life-changing mission to deliver differentiated treatments for those affected by rare and MDR bacterial infections. We seek individuals with unique talents who share our passion.